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Available online 7 June 2016Non-small cell lung cancer (NSCLC) is one of the deadliest cancersworldwide. In search for newNSCLC treatment
options, we screened a cationic amphiphilic drug (CAD) library for cytotoxicity against NSCLC cells and identiﬁed
several CAD antihistamines as inducers of lysosomal cell death.We thenperformed a cohort study on the effect of
CAD antihistamine use on mortality of patients diagnosed with non-localized cancer in Denmark between 1995
and 2011. The use of the most commonly prescribed CAD antihistamine, loratadine, was associated with signif-
icantly reduced all-cause mortality among patients with non-localized NSCLC or any non-localized cancer when
comparedwith use of non-CAD antihistamines and adjusted for potential confounders. Of the less frequently de-
scribed CAD antihistamines, astemizole showed a similar signiﬁcant association with reduced mortality as
loratadine among patients with any non-localized cancer, and ebastine use showed a similar tendency. The asso-
ciation between CAD antihistamine use and reducedmortality was stronger among patients with records of con-
current chemotherapy than among those without such records. In line with this, sub-micromolar concentrations
of loratadine, astemizole and ebastine sensitized NSCLC cells to chemotherapy and revertedmultidrug resistance
in NSCLC, breast and prostate cancer cells. Thus, CAD antihistamines may improve the efﬁcacy of cancer
chemotherapy.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Non-small cell lung cancer (NSCLC) is one of themost common can-
cers and the leading cause of cancer death worldwide (Siegel et al.,
2015). The majority of patients are diagnosed only after the disease
has spread beyond the primary site. Thus, systemic chemotherapy, usu-
ally with combinations containing platinum-based and microtubule-
disturbing drugs, forms the foundation of the treatment of these pa-
tients. As is the case for most advanced cancers, acquired apoptosis
and therapy resistance pose, however, major challenges for the treat-
ment of NSCLC (Chang, 2011). During cancer development, cells accu-
mulate numerous genetic and epigenetic alterations to escape
apoptosis initially induced by the transformation process itself, laterenter for Autophagy, Recycling
randboulevarden 49, DK-2100
en, Denmark.
. This is an open access article underby the hostile tumor environment and ﬁnally by cancer treatment
(Groth-Pedersen and Jäättelä, 2013, Hanahan and Weinberg, 2011).
Moreover, chemotherapy-treated cancer cells often acquire an ability
to efﬂux the chemotherapeutic drugs by increasing the expression of
multidrug resistance (MDR)-associated P-glycoproteins of the ATP-
binding cassette transporter family (Gottesman et al., 2002, Chang,
2011). Importantly, cells harbor alternative cell death pathways that re-
main functional even in otherwise therapy-resistant cancer cells (Fulda,
2014, Kallunki et al., 2013). Of special interest in this context is lysosom-
al cell death. Cancer progression to metastatic disease depends on the
activation of the lysosomal compartment, which is manifested by in-
creased lysosomal biogenesis and acidiﬁcation (Kallunki et al., 2013,
Perera et al., 2015). Besides being tumor-promoting, these lysosomal
changes associate with reduced lysosomal membrane stability
(Fehrenbacher et al., 2008, Fehrenbacher et al., 2004). This frailty of can-
cer cell lysosomes can be targeted by several cationic amphiphilic drugs
(CADs) that accumulate in the acidic lysosomes and induce lysosomal
damage preferentially in cancer cells (Ostenfeld et al., 2008, Petersen
et al., 2013, Sukhai et al., 2013, Jahchan et al., 2013, Shchors et al., 2015).the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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broad spectrumof commondiseases, e.g. psychiatric disorders, allergies,
heart diseases and infections (Kornhuber et al., 2010). They are charac-
terized by a hydrophobic ring structure and a hydrophilic side chain
with a cationic amine group. In acidic milieu, the basic amine groups
are protonated allowing an up to 1000-fold drug accumulation inside
acidic lysosomes (Trapp et al., 2008). The incorporation of CADs into
membranes in the lysosomal lumen neutralizes the negativemembrane
charge thereby inhibiting the function of several lysosomal lipases, in-
cluding acid sphingomyelinase (Kolzer et al., 2004). Cancer cells are es-
pecially sensitive to the accumulation of sphingomyelin
(Barcelo-Coblijn et al., 2011, Teres et al., 2012, Petersen et al., 2013),
which may explain why CADs that are effective acid sphingomyelinase
inhibitors display selective cytotoxicity towards transformed cells
(Petersen et al., 2013, Sukhai et al., 2013, Jahchan et al., 2013, Shchors
et al., 2015).
Repurposing of well-characterized andwell-tolerated drugs for can-
cer therapy has emerged as an attractive alternative for a long and costly
process of drug development. Encouraged by the well-documented
anti-cancer activity of several CADs, we searched systematically for
CADs with highest anti-NSCLC potential by screening a CAD library for
cytotoxicity against A549 NSCLC cells. Prompted by the enrichment of
antihistamines among the hits, we performed a more detailed study of
their cytotoxic activity alone and in combination with chemotherapy,
and conducted a pharmacoepidemiological register-based cohort
study of the association between CAD antihistamine use and mortality
among Danish cancer patients.2. Materials and Methods
2.1. Pharmacoepidemiological Study
To evaluate the association between use of antihistamines andmor-
tality among all Danish residents above 30 years of age diagnosed with
any non-localized cancer (deﬁned based on either regional or distant
metastases) during 1995–2011 or non-localized NSCLC during 2004–
2011 (Supplemental Table S1), we linked data from six nationwide
sociodemographic or health registries described below and in the
Supplemental Table S2 using the personal identiﬁcation number
assigned to all Danish residents (Thygesen et al., 2011). From theDanish
Prescription Registry, we retrieved information on prescriptions
dispensed during 1995–2011 for systemic CAD (astemizole, clemastine,
desloratadine, ebastine, loratadine and terfenadine) and non-CAD
(cetirizine and fexofenadine) antihistamines (Supplemental Table S2).
Ebastine, loratadine, cetirizine and fexofenadine became
available over-the-counter during the study period. The majority of
the antihistamine sale (ebastine N75%, loratadine N65%, cetirizine
N55% and fexofenadine N97%) was, however, by prescription
(Sundhedsdatastyrelsen, 2016). We deﬁned antihistamine (CAD or
non-CAD) use as one ormore prescriptionswithin 0–6month following
the diagnosis of any non-localized cancer and from threemonths before
until threemonths after the non-localizedNSCLCdiagnosis. The patients
were followed from six (all non-localized cancers) or three (non-local-
ized NSCLC) months after the diagnosis until death, emigration, or end
of study (31December 2013),whichever occurredﬁrst. Cox proportion-
al hazards regression was used to estimate hazard ratios (HRs) and 95%
conﬁdence intervals (CIs) for all-causemortality associatedwith the use
of antihistamines. The time since baseline was used as the underlying
time-scale. We compared users of CAD antihistamines with non-users,
as well as with users of either of the two non-CAD antihistamines
fexofenadine or cetirizine, while adjusting for covariates identiﬁed
fromprescription andpatient registries (Tables S3 and S4).We repeated
the analyses stratiﬁed according to records of chemotherapy (yes/no)
during the ﬁrst six months following the diagnosis, which were avail-
able only for patients diagnosed between 2002–2011.The HR estimates for all-cause death associated with use of antihis-
taminewere adjusted for age, year of cancer diagnosis, highest achieved
education, disposable income, Charlson Comorbidity Index score and
drugs as described below. From the Prescription Registry (Kildemoes
et al., 2011), we obtained information on prescriptions of aspirin, non-
aspirin nonsteroidal anti-inﬂammatory drugs (NA-NSAID), statins and
inhibitors of the renin-angiotensin system (including angiotensin
converting enzyme inhibitors (ACEi) and angiotensin-receptor blockers
(ARB)). Use of the ‘confounder drugs’ was deﬁned as ≥1 prescriptions
within the exposure period for antihistamines. From the DanishNation-
al Patient Registry (Schmidt et al., 2015), we retrieved information on
history (at baseline) of diagnoses of chronic conditions included in the
validated Charlson Comorbidity Index (Charlson et al., 1987) and com-
puted Charlson Comorbidity Index score, categorized as 0, 1 or ≥2.
Socio-economic status one year prior to the cancer diagnosis was esti-
mated by the highest achieved education and the disposable income re-
trieved from registers at Statistics Denmark (Jensen and Rasmussen,
2011, Baadsgaard and Quitzau, 2011).
The local institutional review board and the Danish Data Protection
Agency approved the study and waived the requirement for individual
informed consent. Ethical approval is not required for registry-based
studies in Denmark.2.2. Danish Registries
The Danish Cancer Registry has recorded detailed nationwide infor-
mation on cancer incidence since 1943 and offers an accurate and al-
most complete record of cancer cases (Storm et al., 1997, Gjerstorff,
2011). Cancer diagnoses are recorded according to the International
Classiﬁcation of Diseases, Eighth (ICD-8) or Tenth Revision (ICD-10),
and the International Classiﬁcation of Diseases for Oncology (ICD-O) is
used for coding of topography and morphology (Gjerstorff, 2011). The
Cancer Registry also contains data on clinical stage, categorized as local-
ized, regional, distant, or unknown until 2003 and according to the
tumor-node-metastasis (TNM) system from 2004 to the present
(Storm et al., 1997, Gjerstorff, 2011, Edge and Compton, 2010).
The Danish Prescription Registry consists of records of all drug pre-
scriptions dispensed at pharmacies in Denmark since 1995 (Kildemoes
et al., 2011). The data include the type and amount of drug prescribed
according to the Anatomical Therapeutical Chemical (ATC) classiﬁcation
system (WHO, 2013), number of packages, and the date of dispensing at
the pharmacy. The dosing schedule and indication(s) are not recorded,
and no information is available on drug use dispensed at hospital level.
The Danish National Patient Registry contains detailed individual data
on all somatic hospitalizations inDenmark since 1977 andon ambulato-
ry hospital contacts and psychiatric admissions since 1995 (Schmidt et
al., 2015). Discharge and contact diagnoses are coded according to
ICD-8 from 1977 to 1993 and ICD-10 from 1994 to the present. Informa-
tion onmain types of oncological therapy (chemotherapy, radiotherapy,
endocrine therapy, etc.) is available from 2002.
The Danish Register of Causes of Death contains information on date
and cause of death of all inhabitants of Denmark, classiﬁed according
to ICD-8 until 1993 and to ICD-10 from 2004 (Helweg-Larsen, 2011).
Statistics Denmark administers registries on socio-economic data, in-
cluding education and income, of all Danish residents (Jensen and
Rasmussen, 2011, Baadsgaard and Quitzau, 2011).
The Population Education Register holds information on the highest
completed level of education, derived from type and duration of school-
ing (Baadsgaard and Quitzau, 2011).
TheDanish Civil Registration Systemmaintains the civil registry num-
ber (encoding gender and date of birth) assigned to all Danish residents
since 1968 and contains continuously updated address, date of death,
and migration to and from Denmark. Use of the civil registration num-
ber ensures unambiguous linkage between population-based registries
(Thygesen et al., 2011, Schmidt et al., 2014).
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A549 (ATCC® CCL-185™), NCI-H1299 (ATCC® CRL-5803™) and
NCI-H661 (ATCC® HTB-183™) NSCLC cell lines, DU145 prostate cancercell line (ATCC® HTB-81™) and MDA-MB-231 breast cancer cell line
(ATCC® HTB-26™) were obtained from American Type Culture Collec-
tion (ATCC). The cells were authenticated by the ATCC by short tandem
repeat analysis, and they were used within 6 months after thawing.
133A.-M. Ellegaard et al. / EBioMedicine 9 (2016) 130–139Multidrug-resistant variants of DU145 cells (DU145-MDR) and MDA-
MB-231 (MDA-MB-231-MDR) have been described previously
(Ellegaard et al., 2013, Hansen et al., 2015). Themultidrug resistant var-
iant of A549 cells (A549-MDR) were derived by repeated 3-day treat-
ments of A549 cells with increasing doses of vinorelbine up to
150 nM. The parental cells (DU145-P, MDA-MB-231-P and A549-P, re-
spectively) were grown in parallel. The NIH-3T3 ﬁbroblasts transduced
with either the empty pBabe-puro retrovirus or the c-SrcY527F-contain-
ing pBabe-puro retrovirus have been described elsewhere
(Fehrenbacher et al., 2004), and their identity has been conﬁrmed
with RNA-Seq (Petersen et al., 2013). The A549, NCI-H661, NCI-H1299
and DU145 cells were cultured in RPMI-1640 (Gibco, 61870-010) sup-
plemented with 10% (A549, NCI-H661 and NCI-H1299) or 6% (DU145)
heat-inactivated fetal calf serum (Gibco, 10270). The MDA-MB-231
andNIH-3T3 cells were cultured in Dulbecco'sModiﬁed Eagle'smedium
(Gibco, 31966-021) supplemented with 10% heat-inactivated fetal calf
serum and for the NIH-3T3 cells also with non-essential amino acids
(Gibco, 11140-035). All cells were kept at 37 °C in a humidiﬁed atmo-
sphere of 5% CO2. All cells were regularly tested and found negative
for mycoplasma.
The providers, catalog numbers, and CASnumbers of the compounds
in the CAD library are listed in Supplemental Table S5. O-desmethyl-
astemizole (D290750) was purchased from Toronto Research
Chemicals, cisplatin (P4394), cetirizine (C3618), propidium iodide
(P4864), necrostatin-1 (N9037), docetaxel (01885), vinorelbine
ditartrate salt (V2264), fexofenadine hydrochloride (F9427), ebastine
(E9531), KO143 (K2144) and Hoechst-33342 (B2261) from Sigma;
benzyloxycarbonyl-Val-Ala-Asp (OMe)ﬂuoromethylketone (zVAD-
fmk) (N1510-0025) from Bachem; leucin-leucin-O-methyl (LLOMe)
(sc-285992) and carebastine (sc-211022) from Santa Cruz Biotechnolo-
gy; PSC833 (ab145870) from Abcam; cyclizine hydrochloride
(C3090000) from European Pharmacopoeia Reference Standard; and
meclizine dihydrochloride (155341) fromMP Biochemicals. Siramesine
was kindly provided by Christiane Volbracht and A. Bredal Christensen
(H. Lundbeck A/S, Valby, Denmark).
2.4. Viability and Cell Death Assays
Cell death was measured after 15min propidium iodide (0.2 μg/mL)
and Hoechst-33342 staining (2.5 μg/mL) at 37 °C employing Celígo®
Imaging Cytometer (Nexcelom Bioscience) according to the
manufacturer's manual. Apoptotic nuclear condensation was evaluated
in Hoechst-33342 stained cells using Olympus IX81 microscope with a
20× Olympus objective, Scan^R automated acquisition software
(version 2.3.0.5) and analysis with ImageJ (version 1.48v). To evaluate
clonogenic survival, cells were seeded at approximately 400 cells/well
in 24-well plates, treated as indicated, stained with crystal violet-meth-
anol for 15min,washed three times inH2O, dried and analyzedwith the
colony veriﬁcation application of the Celígo® Imaging Cytometer.
Lysosomal membrane permeabilization was detected by staining
paraformaldehyde-ﬁxed cells on glass coverslides with antibodies
recognizing LGALS-1 (Abcam, ab25138) and LAMP2 (Developmental
Studies Hybridoma Bank, H4B4-S) followed by AlexaFluor488- or
AlexaFluor594–coupled secondary antibodies (Molecular Probes,
A21206 and A21203, respectively) as described previously (Aits et al.,
2015). Hoechst-33342 staining was used to visualize the DNA. TheFig. 1. Identiﬁcation and characterization of cytotoxic CADs.(a) Induction of cell death by the te
ment of A549 cells at 10 or 50 μM.(b)Mean LC50 and GI50 values for 29 of the hits from the CAD
from theNCI homepage (NCI, 2015).(c) Death of A549 cells (PI exclusion) induced by treatment
with asterisks.(d) LC50 values for the selected CAD antihistamines in indicated NSCLC cell lines
treated for 24 h as indicated and stained for LGALS1, lysosomal-associated membrane protein
puncta (right). L-Leucyl-L-leucineO-Methyl ester (LLOMe) and fexofenadine served as positive a
were counted. Scale bars, 50 μm. See also Supplemental Fig. 1c.(f) Death of A549 cells (PI exclusi
or without a 1 h pre-treatment with 20 μM z-VAD-fmk, 10 μMnecrostatin-1 or 1 μM ferrostatin
ment with indicated concentrations of CAD antihistamines.Error bars, SD for at least three inde
cells with untreated cells (e) or NIH-3T3-vector cells with NIH-3T3-c-srcY527F (g) in a two-waysamples were mounted with Pro-Long Gold anti-fade (Molecular
Probes, P36935) and confocal ﬂuorescent images were obtained with
Carl Zeiss Axiovert LSM700 microscope with a 40× Carl Zeiss objective
and the Zen 2010 software.
2.5. Western Blot Analysis
Proteins separated in a 6–15% gradient SDS-PAGE and transferred to
a nitrocellulose membrane were visualized with primary antibodies
against MDR1 (Santa Cruz Biotechnology, sc-13131), alpha-tubulin
(Abcam, ab15246) and GAPDH (AbD Serotec, MCA4740), horseradish
peroxidase-conjugated secondary antibodies (anti-mouse, Dako,
P0260; anti-rabbit, Vector Laboratories, PI-1000), and ECLWestern blot-
ting reagents (BIORAD, 170-5061) employing Luminescent Image Read-
er (Fujiﬁlm, LAS-4000).
2.6. Rhodamine123 Assay
Cells were pre-treated for 1 h with 0.25 μg/mL Rhodamine123
(Invitrogen, 890808), treated as indicated for 2 h,washed in clearmedi-
um, stained with Hoechst-33342 and analyzed with the target 1 + 2
(Merge) application of the Celígo® Imaging Cytometer. Hoechst-
33342 staining was used to verify equal cell number in the wells.
2.7. Statistical Analysis
The proportional hazards assumption for the registry-based study
was assessed by testing for trends in the scaled Schoenfeld residuals.
All analyses were performed in R version 3.0.2 using the packages sur-
vival (Therneau, 2014) and Epi (Carstensen et al., 2014). Level of signif-
icance was set to 5% in all analyses. The statistical signiﬁcance of the
experimental results was analyzed by a two-way ANOVA test followed
by Dunnett's, Sidak's or Tukey's multiple comparisons tests (α =
0.05) using GraphPad Prism version 6.0e.
3. Results
3.1. A Screen for CADs That Kill NSCLC Cells
To identify clinically relevant drugs that could complement the
existing NSCLC therapy, we screened a CAD library, containing 72
drugs selected based on their clinical safety proﬁles and reported ability
to inhibit acid sphingomyelinase (Kornhuber et al., 2008, Kornhuber et
al., 2010) for cytotoxicity against A549NSCLC cells. The tenmost potent
drugs induced over 40% cell death at 10 μM and included two antihista-
mines, three antipsychotics, an antiangial, an antidepressant, an antima-
larial, an antiprotozolal and an anti-inﬂammatory natural product
(Fig. 1a). Fifty of the tested drugs induced over 40% cell death at
50 μM (Supplemental Table S5). The National Cancer Institute (NCI)
homepage contains growth inhibition (GI50) and cytotoxicity (LC50)
data for 29 of these compounds screened in a panel of 60 human
tumor cell lines, including nine NSCLC cell lines (NCI, 2015). The mean
GI50 and LC50 values for these CADs ranged from 0.02–14.2 μM and
from 3.89–65.9 μM, respectively (Fig. 1b). All 29 CADs had strikingly
similar dose response curves in the 60 cell lines tested indicating that
their efﬁcacy is not limited to NSCLC or cancers with speciﬁc geneticnmost cytotoxic drugs identiﬁed in a CAD library screen for PI exclusion after a 48 h treat-
library screen in 60 human cancer cell lines (NCI-60 panel) treated for 48 hwere extracted
with 10 or 50 μMof indicated antihistamines for 48 h. Non-CADantihistamines aremarked
as analyzed by a 48 h PI exclusion assay.(e) Representative confocal images of A549 cells
-2 (LAMP2) and DNA (Hoechst-33342) (left), and quantiﬁcation of cells with ≥3 LGALS1
nd negative controls, respectively. Aminimumof 100 randomly chosen cells per condition
on) induced by a 48 h treatmentwith indicated concentrations of CAD antihistamineswith
-1.(g) Death of NIH-3T3-vector and c-srcY527F cells (PI exclusion) induced by a 28 h treat-
pendent triplicate experiments.*p b 0.05, **p b 0.01, ***p b 0.001 when comparing treated
ANOVA followed by Dunnett's (e) or Sidak's (g) multiple comparisons tests.
Fig. 2. Consort ﬂow diagram of the cohort studies.
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among the top ﬁve hits and the favorable safety proﬁles of antihista-
mines, we focused our further investigations on this drug class.
3.2. CAD Antihistamines Destabilize Lysosomal Membranes
To further evaluate the anti-cancer activity of antihistamines, we
ﬁrst tested the cytotoxic potential of seven clinically relevant CAD anti-
histamines and four non-CAD antihistamines in A549 cells. In addition
to terfenadine and astemizole that were among the top hits of our
screen, four CAD antihistamines showed signiﬁcant cytotoxicity against
A549 cells at 50 μM, whereas the remaining three CAD antihistamines
and all four non-CAD antihistamines failed to do so (Fig. 1c). Dose re-
sponse studies of the six most effective CAD antihistamines revealed
similar responses in three NSCLC cell lines (A549, NCI-H1299 and NCI-
H661), where terfenadine had the lowest LC50 values between 5.4–
8.2 μM, followed by astemizole (11.1–15.8 μM), ebastine (18.0–
21.8 μM), clemastine (32.8–40.0 μM), desloratadine (59.5–89.4 μM)
and loratadine (60.1–85.6 μM) (Fig. 1d and Supplemental Fig. S1a).
These values are similar to the available mean LC50 values extracted
from the NCI screen of 60 human cancer cell lines, i.e. 6.4 μM for
terfenadine, 8.0 μM for astemizole, 38.3 μM for clemastine and
65.9 μM for loratadine (Fig. 1b). The active metabolites of terfenadine
(fexofenadine) and ebastine (carebastine) showed no cytotoxicity
against NSCLC cells, the primary metabolite of astemizole (O-
desmethyl-astemizole) retained approximately half of the potency of
the parent compound, and loratadine and its primary metabolite
(desloratadine) showed similar potency (Fig. 1d; Supplemental Figs.
S1a and b; data not shown).
Consistent with the reported ability of several CADs to induce lyso-
somal membrane permeabilization in other cancer cells (Petersen et
al., 2013, Ostenfeld et al., 2008, Ellegaard et al., 2013, Sukhai et al.,
2013), the cytotoxic CAD antihistamines induced lysosomal LGALS1(galectin-1) puncta formation, a hallmark of lysosomal leakage (Aits
et al., 2015), in A549, NCI-H1299 and NCI-H661 cells at concentrations
around their LC50 values (Fig. 1e; Supplemental Fig. S1c; data not
shown). Inhibition of apoptosis, necroptosis or ferroptosis by z-VAD-
fmk, necrostatin-1 or ferrostatin-1, respectively, had no effect on the
cell death induced by CAD antihistamines (Fig. 1f). Finally, the CAD an-
tihistamines induced cell death in c-SrcY527F–transformed NIH-3T3mu-
rine embryonic ﬁbroblasts to a signiﬁcantly higher extent than in the
corresponding vector control cells (Fig. 1g). Taken together, these data
show that CAD antihistamines induce cancer-speciﬁc lysosomal cell
death in NSCLC cells.
3.3. Use of Astemizole and Loratadine is Associated With Reduced Cancer
Mortality
Prompted by the cancer-speciﬁc cytotoxicity of CAD antihistamines,
we conducted a nationwide pharmacoepidemiological cohort study of
the association between the use of cytotoxic CAD antihistamines de-
scribed above within six months after the diagnosis and mortality
among all patients with any non-localized cancer (Fig. 2 and Supple-
mental Table S2). Astemizole or loratadine use was associated with sig-
niﬁcantly reduced all-causemortality as compared with use of the non-
CAD antihistamines, fexofenadine or cetirizine (Table 1; Supplemental
Tables S3 and S6). The use of ebastine showed a similar tendency, use
of terfenadine and desloratadine was without a signiﬁcant effect, and
clemastine use was associated with a signiﬁcantly increased HR for
mortality among patients with any non-localized cancer (Table 1). Sug-
gestive of a prescribing bias, the use of clemastine increased over six-
fold upon cancer diagnosis in our study cohort (see Supplemental
Table S6 and Discussion).
When stratifying all patients with non-localized cancer according to
the records of chemotherapy within six months after the diagnosis
(available for patients diagnosed at 2002 or later), HRs for all-cause
Table 1
Adjusted HRs and 95% CIs for mortality of patients with any non-localized cancer and ≥1
prescriptions of indicated CAD antihistamines within six months after the diagnosis com-
pared with those with ≥1 prescriptions of non-CAD antihistamines (cetirizine or
fexofenadine). See also Supplemental Tables S3 and S6.
Drug HRa 2.5% 97.5% P N
Astemizole
All patientsb 0.67 0.46 0.98 0.040 38
Clemastine
All patientsb 1.32 1.08 1.60 0.006 154
With chemotherapyc 1.51 1.07 2.14 0.020 45
Without chemotherapyc 1.37 0.87 2.17 0.177 46
Desloratadine
All patientsb 0.94 0.79 1.13 0.524 280
with chemotherapyc 0.79 0.61 1.02 0.071 123
without chemotherapyc 0.97 0.73 1.28 0.832 150
Ebastine
All patientsb 0.82 0.62 1.09 0.181 87
with chemotherapyc 0.81 0.43 1.51 0.505 18
without chemotherapyc 0.94 0.58 1.53 0.806 38
Loratadine
All patientsb 0.90 0.82 0.99 0.042 854
with chemotherapyc 0.76 0.63 0.93 0.009 209
without chemotherapyc 0.85 0.70 1.04 0.125 270
Terfenadine
All patientsb 1.00 0.83 1.20 0.988 166
a The values are adjusted for the year of diagnosis, age, Charlson Comorbidity Index
score, disposable income and use of aspirin, statins, NA-NSAIDs and ACEi-ARB (Supple-
mental Table S4).
b All patients diagnosed with any non-localized cancer in 1995–2011.
c Data stratiﬁed by available (2002−2012) records of chemotherapy (registered, N =
34,394 or non-registered, N = 42,267) within six months after the cancer diagnosis. This
analysis was not applicable for astemizole and terfenadine, which were withdrawn from
the market in 1999 and 2004, respectively.
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clemastine, were lower for patients with recorded chemotherapy than
for those without such records (Table 1).
Low number of non-localized NSCLC patients hampered a similar
analysis of NSCLCmortality formost CAD antihistamines. The aggressive
nature of this disease further reduced the statistical power due to the
high mortality during the ﬁrst six months after the diagnosis. Thus, we
redeﬁned the drug exposure periods from six months after the diagno-
sis to three months before until three months after the diagnosis
(Fig. 2). The use of the most commonly prescribed CAD antihistamine,
loratadine, within this time period showed a statistically signiﬁcant in-
verse association with mortality, and HRs for all-cause mortality
among loratadine users were lower for patients with recorded concur-
rent chemotherapy than for those without such records (Table 2; Sup-
plemental Tables S4 and S7). The effect appeared independent of theTable 2
Adjusted HRs and 95% CIs for the mortality of patients with non-localized NSCLC and ≥1
prescriptions of indicated CAD antihistamines from three months before until three
months after the diagnosis compared with those with ≥1 prescriptions of non-CAD anti-
histamine (cetirizine or fexofenadine). See also Supplemental Tables S4 and S7.
Drug HRa 2.5% 97.5% P N
Clemastine 1.04 0.48 2.25 0.923 9
Desloratadine 1.10 0.79 1.54 0.554 47
Ebastine 0.63 0.26 1.54 0.310 7
Loratadine 0.69 0.49 0.96 0.030 60
With chemotherapyb 0.64 0.42 0.97 0.035 34
Without chemotherapyb 0.81 0.46 1.41 0.457 26
Adenocarcinomac 0.62 0.35 1.08 0.094 22
Squamous cell carcinomac 0.65 0.34 1.25 0.196 18
Other histologyc 0.70 0.40 1.22 0.207 20
a The values are adjusted for the year of diagnosis, age, Charlson Comorbidity Index
score, disposable income and use of aspirin, statins, NA-NSAIDs and ACEi-ARB (Supple-
mental Table S5).
b Data stratiﬁed according to available records of chemotherapy within three months
after the cancer diagnosis.
c Data stratiﬁed according to NSCLC subtypes.cancer histology because HRs for mortalitywere similar among patients
with adenocarcinoma, squamous cell carcinoma and other types of
NSCLC (Table 2).
3.4. Sub-micromolar Concentrations of CAD Antihistamines Revert MDR
Clinically relevant doses of loratadine and astemizole result in plas-
ma concentrations considerably lower than those required for effective
inhibition of NSCLC cell growth or survival in vitro (Heykants et al., 1986,
Hilbert et al., 1987). Thus, the putative anti-cancer effects observed
above were probably not caused by CADs alone but rather by a com-
bined effect of low concentrations of CADs and chemotherapy. MDR1-
mediated resistance to chemotherapy represents one of the major bar-
riers to positive long-term outcomes for this patient group (Chang,
2011), and several CADs have been reported to revert MDR1-associated
drug resistance at micromolar concentrations (Jaffrezou et al., 1995,
Petersen et al., 2013, Ellegaard et al., 2013). Thus, we tested whether
low, clinically relevant concentrations of CAD antihistamines could re-
sensitize MDR1-expressing NSCLC cells to chemotherapy. Because
none of the three NSCLC cell lines used here had detectable MDR1 ex-
pression, we ﬁrst created an MDR-variant of A549 cells by repeated
treatments with increasing concentrations of vinorelbine (Supplemen-
tal Figs. S2a and b). Astemizole, ebastine and loratadine re-sensitized
the obtained A549-MDR cells signiﬁcantly to vinorelbine even at
500 nM, and terfenadine did so at 1 μM, whereas their primary metabo-
lites OD-astemizole, carebastine, desloratadine and fexofenadine, respec-
tively, failed to do so at concentrations up to 2 μM (Fig. 3a; Supplemental
Fig. S2a). Similar MDR1-speciﬁc sensitization to docetaxel was observed
in MDR1-expressing DU145-MDR prostate cancer cells and MDA-MB-
231-MDR breast cancer cells treated with low concentrations of CAD an-
tihistamines (Figs 3b and c; Supplemental Figs. S2d and e).
Astemizole and terfenadine have been reported to inhibit the efﬂux
activity of MDR1 at IC50 of 1.3 and 1.4 μM, respectively (Schwab et al.,
2003). Thus, we tested whether the other CAD antihistamines pos-
sessed similar ability at concentrations relevant for re-sensitization. In-
dicative of MDR1 activity, A549-MDR cells effectively efﬂuxed the
MDR1 substrate Rhodamine123 dye, which was completely inhibited
by 2 μM PSC833 (MDR1 inhibitor) and by 50% by 1 μM astemizole
(Fig. 3d; Supplemental Fig. S3). Ebastine and loratadine failed to inhibit
the dye exclusion at 1 μMsuggesting that CAD antihistamines can revert
drug resistance also by mechanisms other than the direct inhibition of
the efﬂux activity of MDR1 (Fig. 3d).
3.5. CAD Antihistamines and Chemotherapy Synergize to Induce Apoptotic
and Lysosomal Cell Death
To search for MDR1-independent mechanisms of synergy between
CAD antihistamines and chemotherapy, we tested whether low non-
toxic concentrations of CAD antihistamines enhanced the inhibitory ef-
fect of chemotherapy on clonogenic potential of NSCLC cells. Indeed,
sub-micromolar concentrations of astemizole, ebastine, loratadine and
terfenadine potentiated the inhibitory effect of vinorelbine on colony
formation of NCI-H1299 cells, whereas clemastine, desloratadine and
fexofenadine failed to do so (Fig. 4a). Similarly, astemizole, but not
fexofenadine, sensitized NCI-H661 cells to subtoxic concentration of
vinorelbine or cisplatin (Fig. 4b).
To investigate the mechanisms underlying the synergism between
CADs and chemotherapy, we ﬁrst analyzed lysosomal leakage by
counting LGALS1 (galectin 1)-positive lysosomes in NCI-H1299 cells
treated with suboptimal concentrations of astemizole and vinorelbine
for 24–72 h. A non-toxic concentration of astemizole triggered a tran-
sient (24–48 h) accumulation of LGALS1 positive lysosomes, which
were cleared at 72 h (Figs. 4c–d). Addition of vinorelbine at a concentra-
tion, which alone killed approximately 20% of the cells without
disturbing lysosomal membrane integrity, enhanced astemizole-in-
duced lysosomal damage (LGALS1 puncta formation) and inhibited
Fig. 3. The ability of CAD antihistamines to re-sensitize MDR cancer cells to chemotherapy. (a–c) Death of parental (P) andmultidrug resistant (MDR) A549 (a), DU145 (b) andMDA-MB-
231 (c) cells (PI exclusion) induced by a 48 h treatment with indicated chemotherapeutics alone (white bars) or in combination with indicated concentrations of antihistamines. See also
Supplemental Fig. S2c-e. (d) Fluorescence intensity in A549-P and A549-MDR cells treated with Rhodamine123 for 1 h prior to 2 h treatment with indicated concentrations of
antihistamines or MDR inhibitors KO143 (ABCG2) or PSC833 (MDR1) was assessed with the Celígo® Imaging Cytometer (left). Representative images of selected conditions are shown
(right). Scale bars, 100 μm. See also Supplemental Fig. S3. Error bars, SD for three independent, triplicate experiments. *p b 0.05, **p b 0.01, ***p b 0.001 when comparing MDR cells
treated with and without antihistamines (a–c) or when comparing drug-treated and untreated cells (d) in a one-way (d) or two-way (a–c) ANOVA followed by Dunnett's multiple
comparisons tests.
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cell death (Figs. 4c–e). Contrary to CAD-induced cell death that is inde-
pendent of caspases (Fig. 1f), the pan-caspase inhibitor z-VAD-fmk
inhibited approximately 60% of the cell death induced by vinorelbine
alone or in combination with astemizole (Fig. 4e). These data suggest
that the synergistic effect of astemizole and vinorelbine in NCI-H1299
cells results from the enhancement of both lysosomal and caspase-de-
pendent cell death pathways.
4. Discussion
Data presented above suggest that addition of clinically relevant
doses of well-tolerated CAD antihistamines to the standard cancer che-
motherapy regiment improves cancer prognosis. This conclusion isbased on statistically signiﬁcant inverse associations between the use
of loratadine, or the use of either loratadine or astemizole, and all-
cause mortality among Danish patients with non-localized NSCLC or
any non-localized cancer, respectively. Furthermore, ebastine use was
associated with reduced all-cause mortality, albeit not statistically sig-
niﬁcant, in both study cohorts. Importantly, use of non-CAD antihista-
mines, fexofenadine and cetirizine, which have similar antihistamine
effects and are prescribed for similar indications as CAD antihistamines,
did not affect cancermortality. Thus, the observed positive effect of CAD
antihistamines is likely to be related to their CAD structure rather than
their antihistamine effect or the disease they have been prescribed for.
Our pharmacoepidemiological study was inspired by the ability of
CAD antihistamines to induce cancer-speciﬁc lysosomal cell death in
vitro. The putative clinical beneﬁt of CAD antihistamines is, however,
Fig. 4. The ability of CAD antihistamines to sensitize NSCLC cells to chemotherapy. (a and b) Clonogenic survival of NCI-H1299 (a) and NCI-H661 (b) cells treated with indicated
combinations of CADs and chemotherapy for four days. (c–e) Representative confocal images of NCI-H1299 cells treated for 72 h as indicated and stained for LGALS1, LAMP2 and DNA
(Hoechst-33342) (c), and quantiﬁcation of cells with ≥3 LGALS1 puncta (d) and cell death (e) after similar treatment for 24–72 h. When indicated, cells were pre-treated with 20 μM
z-VAD-fmk for 1 h (e). Scale bars, 25 μm. A minimum of 50 cells per condition were counted in (d). Error bars, SD for a minimum or three (a, b and e) or 2–3 (d) independent,
triplicate experiments. *p b 0.05, **p b 0.01, ***p b 0.001 when comparing cells as indicated in a two-way ANOVA followed by Dunnett's (a, b), Tukey's (d) or Sidak's (e) multiple
comparisons tests.
137A.-M. Ellegaard et al. / EBioMedicine 9 (2016) 130–139not likely to be due to their direct cytotoxicity alone. Their LC50 and GI50
values are signiﬁcantly higher than reported plasma concentrations
achieved with recommended doses of these drugs, which range from
undetectable for ebastine to 11 nM for astemizole and 68 nM for
loratadine (Del Cuvillo et al., 2006). Instead, their ability to sensitize
cancer cells to chemotherapy and revert MDR phenotype at sub-micro-
molar concentrations may explain the positive effects observed in ourregister-based study. This assumption is supported by the subgroup
analyses showing that patients with records of chemotherapy within
six months following the diagnosis of non-localized cancer or within
three months of the diagnosis of non-localized NSCLC had additionally
reduced HRs for all-cause mortality.
Interestingly, all three antihistamines emerging as putative anti-can-
cer drugs in our studies have extremely high apparent volumes of
Table 3
Apparent volumes of distribution (VD) of selected antihistamines.
Drug VD (L/kg) Reference
Astemizole 48 Tillement (2000)
Clemastine 11.4a Schran et al. (1996)
Desloratadine 49 Molimard et al. (2004)
N100 Del Cuvillo et al. (2006)
Ebastine N100 Del Cuvillo et al. (2006)
Loratadine 120 Tillement (2000)
Terfenadine 2.2–2.9 Tillement (2000)
Cetirizine 0.4 Tillement (2000)
0.5 Del Cuvillo et al. (2006)
Fexofenadine 5.6 ± 0.7 Tillement (2000)
a The VD value given in liters (L) was converted to L/kg by dividing with an estimated
average weight of 70 kg for the men included in the study.
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(Tillement, 2000), loratadine (Tillement, 2000) and ebastine (Del
Cuvillo et al., 2006) (Table 3). High VD values reﬂect the efﬁcient distri-
bution of drugs to tissues. Accordingly, the reported concentrations of
astemizole in e.g. lungs, kidneys, liver and pancreas of Beagle dogs treat-
ed for six weeks with 1 mg/kg astemizole are over 1000-fold higher
than the corresponding plasma concentrations (Tillement, 2000,
Michiels et al., 1986). Notably, astemizole and other CADs, which per
deﬁnition are weak bases, are likely to accumulate in acidic tumors
even more efﬁciently than in healthy tissues with neutral pH. Data for
tissue distribution of loratadine and ebastine are unfortunately not
available, but their higher VD values suggest even more efﬁcient tissue
distribution than observed for astemizole. On the other hand, the ap-
proximately 50-fold lower VD (Tillement, 2000) and less efﬁcient tissue
distribution of terfenadine (Leeson et al., 1982) may explain the dis-
crepancy between its potent anti-cancer activity in vitro and lack of ef-
fect in the pharmacoepidemilogical study. Contrary to the other CADs
studied here, clemastine usewas associatedwith increased cancermor-
tality. Notably, clemastine is commonly used in prevention and treat-
ment of hypersensitivity reactions associated with cancer therapy at
Danish hospitals and its use increased over six-fold after cancer diagno-
sis in our patient cohort. Such a prescription bias towards high-risk pa-
tients may thus explain the poor prognosis associated with the use of
clemastine. It should also be noted that clemastine has a relatively low
VD value (Schran et al., 1996) (Table 3), and its ability to augment che-
motherapy in parental andMDR cancer cells in vitro is inferior to that of
astemizole, loratadine and ebastine. Over-the-counter sale of loratadine
(b35% of the total sale) and ebastine (b25%) could create another po-
tential source of bias. Such exposure misclassiﬁcation is, however, con-
sidered negligible.
Taken together, the data presented here suggest that repurposing of
safe and inexpensive CAD antihistamines to cancer therapy may en-
hance the anti-neoplastic response of chemotherapy especially in the
case of microtubule-disturbing drugs. Further studies addressing the
dose-responses and tissue distribution of CAD antihistamines and efﬁ-
cacy of various treatment combinations in pre-clinical animal models
will hopefully pave the way for subsequent clinical trials in patients
with distant stage NSCLC as well as other advanced cancers in near
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